Intravesical BCG Treatment for Superficial Bladder Cancer: Long‐term Results using Two Different Strains of BCG

Abstract
A total of 21 patients received intravesical BCG for the prevention of recurrence of superficial transitional cell carcinoma of the bladder. Twelve patients received the Glaxo strain and 9 the Pasteur strain of the bacillus. Although thought to have different anti‐tumour activities owing to a difference in antigenicity, these 2 strains produced similar tumour‐free rates at 5 years' mean follow‐up with an overall tumour‐free rate of 43%.